REGENXBIO (NASDAQ:RGNX – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Tuesday. RGNX has been the topic of a ...
As the world recognizes Rare Disease Day on Feb. 28, Rockville-based biotechnology company, REGENXBIO is working to change ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, March 13, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended ...
REGENXBIO (NASDAQ:RGNX – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, ...
ABOUT REGENXBIO Inc. REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has ...
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...
Leerink Partners analyst Mani Foroohar maintained a Buy rating on RegenXBio (RGNX – Research Report) on February 20 and set a price target of ...
Goldman Sachs made a significant adjustment to its stance on Regenxbio Inc . (NASDAQ:RGNX), downgrading the stock from "Buy" to "Neutral" and reducing the price target dramatically to $14.00 from the ...
Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...
RegenXBio (RGNX – Research Report) received a Hold rating and price target from Goldman Sachs analyst Paul Choi today. The company’s shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback